- Home
- LPCN vs ABP Comparison
LPCN vs ABP Comparison
Compare LPCN & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- ABP
- Stock Information
- Founded
- LPCN 1997
- ABP 2004
- Country
- LPCN United States
- ABP United States
- Employees
- LPCN N/A
- ABP N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- ABP Health Care
- Exchange
- LPCN Nasdaq
- ABP Nasdaq
- Market Cap
- LPCN 18.2M
- ABP 15.2M
- IPO Year
- LPCN N/A
- ABP N/A
- Fundamental
- Price
- LPCN $2.60
- ABP $0.20
- Analyst Decision
- LPCN Strong Buy
- ABP Hold
- Analyst Count
- LPCN 1
- ABP 1
- Target Price
- LPCN $8.00
- ABP N/A
- AVG Volume (30 Days)
- LPCN 59.9K
- ABP 4.6M
- Earning Date
- LPCN 11-07-2025
- ABP 11-18-2025
- Dividend Yield
- LPCN N/A
- ABP N/A
- EPS Growth
- LPCN N/A
- ABP N/A
- EPS
- LPCN N/A
- ABP N/A
- Revenue
- LPCN $4,208,119.00
- ABP $183,000.00
- Revenue This Year
- LPCN N/A
- ABP N/A
- Revenue Next Year
- LPCN N/A
- ABP N/A
- P/E Ratio
- LPCN N/A
- ABP N/A
- Revenue Growth
- LPCN N/A
- ABP 154.17
- 52 Week Low
- LPCN $2.57
- ABP $0.15
- 52 Week High
- LPCN $6.17
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- LPCN 32.60
- ABP 46.19
- Support Level
- LPCN $2.75
- ABP $0.19
- Resistance Level
- LPCN $2.92
- ABP $0.21
- Average True Range (ATR)
- LPCN 0.14
- ABP 0.02
- MACD
- LPCN -0.05
- ABP 0.00
- Stochastic Oscillator
- LPCN 4.69
- ABP 42.34
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.